EUVIMEDEUVIMED entdecken
Open Access

Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells

Heng Liu, Cheng Xu, Bill H Diplas, Alexandrea Brown, Laura M Strickland, Haipei Yao, Jinjie Ling, Roger E McLendon, Stephen T Keir, David M Ashley, Yiping He, Matthew S Waitkus iD

Neuro-Oncology · 05.09.2023 · 25 (9) · 1563-1575

DOI: 10.1093/neuonc/noad022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 23.01.2023. Verfasst von Heng Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Telomerase, Glioblastoma. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, The Preston Robert Tisch Brain Tumor Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Telomere maintenance mechanisms are required to enable the replicative immortality of malignant cells. While most cancers activate the enzyme telomerase, a subset of cancers uses telomerase-independent mechanisms termed alternative lengthening of telomeres (ALT). ALT occurs via homology-directed-repair mechanisms and is frequently associated with ATRX mutations. We previously showed that a subset of adult glioblastoma (GBM) patients with ATRX-expressing ALT-positive tumors harbored loss-of-function mutations in the SMARCAL1 gene, which encodes an annealing helicase involved in replication fork remodeling and the resolution of replication stress. However, the causative relationship between SMARCAL1 deficiency, tumorigenesis, and de novo telomere synthesis is not understood.

Methods

We used a patient-derived ALT-positive GBM cell line with native SMARCAL1 deficiency to investigate the role of SMARCAL1 in ALT-mediated de novo telomere synthesis, replication stress, and gliomagenesis in vivo.

Results

Inducible rescue of SMARCAL1 expression suppresses ALT indicators and inhibits de novo telomere synthesis in GBM and osteosarcoma cells, suggesting that SMARCAL1 deficiency plays a functional role in ALT induction in cancers that natively lack SMARCAL1 function. SMARCAL1-deficient ALT-positive cells can be serially propagated in vivo in the absence of detectable telomerase activity, demonstrating that the SMARCAL1-deficient ALT phenotype maintains telomeres in a manner that promotes tumorigenesis.

Conclusions

SMARCAL1 deficiency is permissive to ALT and promotes gliomagenesis. Inducible rescue of SMARCAL1 in ALT-positive cell lines permits the dynamic modulation of ALT activity, which will be valuable for future studies aimed at understanding the mechanisms of ALT and identifying novel anticancer therapeutics that target the ALT phenotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelomeraseGlioblastomaHumansTelomere HomeostasisMutationTelomereCarcinogenesisCell Transformation, NeoplasticDNA Helicases

Stichwörter der Autor:innen

ATRXAdult gliomasSMARCAL1alternative lengthening of telomeresgliomagenesistelomere maintenance

Substanzen

TelomeraseSMARCAL1 protein, humanDNA Helicases

Autor:innen und Institutionen

  • The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA.
  • Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.
  • Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.

ORCID-Profile: Matthew S Waitkus

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • The Preston Robert Tisch Brain Tumor Center
  • National Institutes of Health

Zitieren

APA

Liu, H., Xu, C., Diplas, B. H., Brown, A., Strickland, L. M., Yao, H., Ling, J., McLendon, R. E., Keir, S. T., Ashley, D. M., He, Y., & Waitkus, M. S. (2023). Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells. Neuro-Oncology, 25(9), 1563-1575. https://doi.org/10.1093/neuonc/noad022

Vancouver

Liu H, Xu C, Diplas BH, Brown A, Strickland LM, Yao H, et al. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells. Neuro-Oncology. 2023;25(9):1563-1575. doi:10.1093/neuonc/noad022

BibTeX
@article{Liu2023,
  author = {Liu, Heng and Xu, Cheng and Diplas, Bill H and Brown, Alexandrea and Strickland, Laura M and Yao, Haipei and Ling, Jinjie and McLendon, Roger E and Keir, Stephen T and Ashley, David M and He, Yiping and Waitkus, Matthew S},
  title = {Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells},
  journal = {Neuro-Oncology},
  year = {2023},
  volume = {25},
  number = {9},
  pages = {1563--1575},
  doi = {10.1093/neuonc/noad022}
}
Kostenlos starten →